Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Srilata Gundala

Hematology & Oncology Hinsdale, IL Medical Doctor

NPI 1467646141 CMS profile 67012

950 N York Rd Ste 201A, Hinsdale, IL 60521

Open in the dashboard

General payments

$10,862

406 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,265,973 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Srilata Gundala of Hinsdale, IL is reported in the CMS Open Payments database as having received $10,862 across 406 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,265,973 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,631 118
2024 General $2,899 105
2023 General $1,984 71
2022 General $912 44
2021 General $643 25
2020 General $271 14
2019 General $522 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srilata Gundala
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Srilata Gundala were reported at $3,631. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Srilata Gundala Hematology & Oncology median Middle half National median
2019 $522 $529 $121–$2,516 $163
2020 $271 $339 $82–$2,213 $114
2021 $643 $263 $49–$1,965 $132
2022 $912 $416 $103–$2,395 $149
2023 $1,984 $542 $125–$2,646 $160
2024 $2,899 $692 $141–$3,008 $164
2025 $3,631 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,931 46 payments
  2. Genentech USA, Inc. $871 33 payments
  3. Janssen Biotech, Inc. $664 26 payments
  4. AstraZeneca Pharmaceuticals LP $643 28 payments
  5. Pfizer Inc. $533 23 payments
  6. Lilly USA, LLC $501 19 payments
  7. Celgene Corporation $497 18 payments
  8. Merck Sharp & Dohme Corporation $363 19 payments
  9. Daiichi Sankyo Inc. $321 11 payments
  10. E.R. Squibb & Sons, L.L.C. $300 15 payments
  11. Other $4,239 168 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,068 388 payments
  2. Long term medical supply or device loan $1,280 13 payments
  3. Education $514 5 payments
Products named General payments · program years 2019–2025
  1. KISQALI $1,528 25 payments
  2. TECENTRIQ $428 19 payments
  3. KEYTRUDA $342 18 payments
  4. DARZALEX $319 12 payments
  5. TALVEY $293 10 payments
  6. Phesgo $290 13 payments
  7. TUKYSA $234 9 payments
  8. XTANDI $234 9 payments
  9. ENHERTU $231 6 payments
  10. INLYTA $223 8 payments
  11. Other $8,560 390 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

239

Median for Hematology-Oncology: 604

Drug cost

$592,605

Median for Hematology-Oncology: $1,306,514

Branded share of claims

34.3%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lenalidomide Generic 24 $321,117
Darzalex Daratumumab Brand 15 $211,188
Venclexta Venetoclax Brand 15 $38,071
Prolia Denosumab Brand 11 $18,406
Exemestane Generic 15 $1,111
Anastrozole Generic 75 $1,092
Ondansetron Odt Ondansetron Brand 22 $782
Prochlorperazine Maleate Generic 18 $405
Valacyclovir Valacyclovir Hcl Brand 19 $282
Gabapentin Generic 14 $82

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$974,234

Of which drugs: $864,172

Medicare patients

181

Average age 75

Services billed

71,154

126 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Cancer 47%
Diabetes 44%
Ischemic heart disease 36%
Chronic kidney disease 36%
Atrial fibrillation 27%
Osteoporosis 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ferric derisomaltose, 10 mg J1437 Office 22 2,702 $42,643
Injection, palonosetron hcl, 25 mcg J2469 Office 12 901 $606
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 701 $63

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 55 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $506
$506 — —
ENHERTU
  • Daiichi Sankyo Inc. $76
  • AstraZeneca Pharmaceuticals LP $47
$123 — —
Padcev
  • Astellas Pharma US Inc $62
  • PFIZER INC. $56
$118 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $90
$90 — —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 55 with Patron

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record